Abstract:Smallpox was the most rampant infectious disease killer of the 20 th century, yet much remains unknown about the pathogenesis of the variola virus. Using archived tissue from a study conducted at the Centers for Disease Control and Prevention we characterized pathology in 18 cynomolgus macaques intravenously infected with the Harper strain of variola virus. Six macaques were placebo-treated controls, six were tecovirimat-treated beginning at 2 days post-infection, and six were tecovirimat-treated beginning at 4 days post-infection. All macaques were treated daily until day 17. Archived tissues were interrogated using immunohistochemistry, in situ hybridization, immunofluorescence, and electron microscopy. Gross lesions in three placebo-treated animals that succumbed to infection primarily consisted of cutaneous vesicles, pustules, or crusts with lymphadenopathy. The only gross lesions noted at the conclusion of the study in the three surviving placebo-treated and the Day 4 treated animals consisted of resolving cutaneous pox lesions. No gross lesions attributable to poxviral infection were present in the Day 2 treated macaques. Histologic lesions in three placebo-treated macaques that succumbed to infection consisted of proliferative and necrotizing dermatitis with intracytoplasmic inclusion bodies and lymphoid depletion. The only notable histologic lesion in the Day 4 treated macaques was resolving dermatitis; no notable lesions were seen in the Day 2 treated macaques. Variola virus was detected in all three placebo-treated animals that succumbed to infection prior to the study's conclusion by all utilized methods (IHC, ISH, IFA, EM). None of the three placebo-treated animals that survived to the end of the study nor the animals in the two tecovirimat treatment groups showed evidence of variola virus by these methods. Our findings further characterize variola lesions in the macaque model and describe new molecular methods for variola detection. The worldwide 2022 mpox outbreak renewed research interest in defining and countering threats posed by orthopoxviruses, including smallpox. In the absence of optimized prevention and treatment strategies, natural re-emergence of smallpox or its use as a bioweapon released into unvaccinated populations could result in avoidable illnesses and deaths. Here we applied recently developed techniques to study the relationship between smallpox lesion development and the fate of virus in three groups of animals exposed to smallpox virus: those treated with the FDA-approved antiviral tecovirimat 2 or 4 days after infection and a placebo-treated group. We were able to characterize the development of lesions at gross and microscopic levels and describe new molecular methods for studying the distribution and persistence of variola virus (VARV) in tissue samples that were collected from the three treatment groups. These findings can be used to fine-tune the timing of administering tecovirimat, other antivirals, and vaccines, as well as help characterize the performance of in-development orthopoxvirus countermeasures.

Expansion, Reexpansion, and Recall-Like Expansion of V Gamma 2v Delta 2 T Cells in Smallpox Vaccination and Monkeypox Virus Infection

Retrospective Detection of Monkeypox Virus in the Testes of Nonhuman Primate Survivors.

MPXV Infection Stimulates a More Robust and Durable Neutralizing Antibody Response Compared to MVA-BN Vaccination

The land-scape of immune response to monkeypox virus

Characterizing the acute antibody response of monkeypox and MVA‐BN vaccine following an Australian outbreak

Vaccinia Virus: Mechanisms Supporting Immune Evasion and Successful Long-Term Protective Immunity

Simian Varicella Virus Is Present in Macrophages, Dendritic Cells, and T Cells in Lymph Nodes of Rhesus Macaques after Experimental Reactivation

Transcriptional and functional remodeling of lung-resident T cells and macrophages by Simian varicella virus infection

Characterization and comparison of immunity against MPXV for individuals infected with MPXV or vaccinated with modified vaccinia Ankara vaccines

Cross-reactive antibody response to Monkeypox virus surface proteins in a small proportion of individuals with and without Chinese smallpox vaccination history

Monkeypox virus quadrivalent mRNA vaccine induces antibody responses and cellular immunity and protects mice against Vaccinia virus

Comparison of Transcriptomic Signatures between Monkeypox-Infected Monkey and Human Cell Lines

Smallpox lesion characterization in placebo-treated and tecovirimat-treated macaques using traditional and novel methods

Cross-reactive antibodies against monkeypox virus exist in the population immunized with vaccinia Tian Tan strain in China

Expansion of memory Vδ2 T cells following SARS-CoV-2 vaccination revealed by temporal single-cell transcriptomics

Characterization of the Monkeypox Virus [MPX]-Specific Immune Response in MPX-Cured Individuals Using Whole Blood to Monitor Memory Response

Robust IgM responses following intravenous vaccination with Bacille Calmette–Guérin associate with prevention of Mycobacterium tuberculosis infection in macaques

Duration of humoral immunity from smallpox vaccination and its cross-reaction with Mpox virus

Prime-boost vaccination with recombinant mumps virus and recombinant vesicular stomatitis virus vectors elicits an enhanced human immunodeficiency virus type 1 Gag-specific cellular immune response in rhesus macaques

Antigen-Specific Nk Cell Memory in Rhesus Macaques

Programmable Macrophage Vesicle Based Bionic Self‐Adjuvanting Vaccine for Immunization against Monkeypox Virus